{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:20:08Z","timestamp":1787664008121,"version":"build-2736575974"},"reference-count":199,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal antibodies (mAbs) compared to other drugs, given that the intrinsic properties of immunoglobulin G molecules are generally considered ethnically insensitive. This prompted an evaluation of the currently available evidence for potential PK differences for mAbs between Japanese and Non\u2010Japanese populations. We reviewed 137 mAbs approved in the United States, of which 101 were also approved in Japan, to evaluate whether PK differences between Japanese and non\u2010Japanese individuals have been reported. PK was found to be similar between Japanese and non\u2010Japanese, predominantly Caucasians\/Whites, for 59 out of 101 mAbs. Although PK differences were identified for 26 out of 101 mAbs approved in Japan, these differences were largely attributed to body weight differences between Japanese and non\u2010Japanese populations. After adjusting for these body weight differences, most mAbs demonstrated no meaningful PK differences across the ethnic groups. Importantly, the observed differences were reported not to translate into clinically meaningful impact on pharmacodynamics, safety, and efficacy to warrant different dosing recommendations. No differences in dosing recommendations could be detected for any of the 101 mAbs approved in Japan compared to the United States. Overall, these data suggest a lack of a convincing scientific rationale for the necessity of dedicated PK studies in Japanese versus non\u2010Japanese individuals for mAbs.<\/jats:p>","DOI":"10.1002\/jcph.70245","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:25:55Z","timestamp":1785414355000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non\u2010Japanese Individuals"],"prefix":"10.1002","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9099-5177","authenticated-orcid":false,"given":"Paridhi","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy University of Tennessee Health Science Center  Memphis TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2236-3032","authenticated-orcid":false,"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Boehringer Ingelheim Pharmaceuticals  Ridgefield CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-3648","authenticated-orcid":false,"given":"Bernd","family":"Meibohm","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy University of Tennessee Health Science Center  Memphis TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64552-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000037"},{"key":"e_1_2_9_4_1","volume-title":"Ethnic Factors in the Acceptability of Foreign clinical data E5 (R1): International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","author":"Guideline IH","year":"1998"},{"key":"e_1_2_9_5_1","volume-title":"Notification No. 739 (kyokuchou\u2010tsuuchi)","author":"Pharmaceutical and Medical Safety Bureau, Ministry of Health, Labour and Welfare, Japan","year":"1998"},{"key":"e_1_2_9_6_1","volume-title":"Basic Principles on Global Clinical Trials: September 28, 2007 Notification No. 0928010","author":"Ministry of Health, Labour and Welfare, Japan","year":"2007"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2012.701581"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.285"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.106"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.990438"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1044"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26188794"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011411192"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.231"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1860476"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1703531"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1556465"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1415671"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1269580"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1125583"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2015.989042"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.19931"},{"key":"e_1_2_9_23_1","unstructured":"Drugs@FDA: FDA\u2010approved drugs.https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"e_1_2_9_24_1","unstructured":"Pharmaceutical and Medical Devices Agency of Japan list of approved products.https:\/\/www.pmda.go.jp\/english\/review\u2010services\/reviews\/approved\u2010information\/drugs\/0002.html."},{"key":"e_1_2_9_25_1","volume-title":"Center for Drug Evaluation and Research, Adalimumab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw146"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3999\/jscpt.50.73"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3064"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1583833"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000252"},{"key":"e_1_2_9_31_1","volume-title":"Center for Drug Evaluation and Research, Ansuvimab, Integrated review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0371-6"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.587"},{"key":"e_1_2_9_34_1","volume-title":"Center for Drug Evaluation and Research, Inmazeb, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0903-1"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30239-5"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-025-01438-7"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2506"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/21556660.2013.792823"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12160"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03946-8"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01971-18"},{"key":"e_1_2_9_43_1","volume-title":"Center for Drug Evaluation and Research, Bimekizumab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14322"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.10.009"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4347"},{"key":"e_1_2_9_47_1","volume-title":"Center for Drug Evaluation and Research, Brolucizumab, Clinical review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_48_1","volume-title":"Center for Drug Evaluation and Research, Burosumab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.162"},{"key":"e_1_2_9_50_1","volume-title":"Center for Drug Evaluation and Research, Canakinumab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_51_1","volume-title":"Center for Drug Evaluation and Research, Cemiplimab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_52_1","volume-title":"Center for Drug Evaluation and Research, Certolizumab pegol, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0904-6"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1542"},{"key":"e_1_2_9_55_1","volume-title":"Center for Drug Evaluation and Research, Clesrovimab, Integrated review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13627"},{"key":"e_1_2_9_57_1","volume-title":"Center for Drug Evaluation and Research, Cosibelimab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_58_1","volume-title":"Center for Drug Evaluation and Research, Crizanlizumab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_59_1","volume-title":"Center for Drug Evaluation and Research, Crovalimab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_60_1","volume-title":"Center for Drug Evaluation and Research, Daclizumab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_61_1","volume-title":"Center for Drug Evaluation and Research, Daratumumab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_62_1","volume-title":"Center for Drug Evaluation and Research, Denosumab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_63_1","volume-title":"Center for Drug Evaluation and Research, Depemokimab, Multidisciplinary review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_64_1","volume-title":"Center for Drug Evaluation and Research, Dinutuximab, Clinical review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_65_1","volume-title":"Center for Drug Evaluation and Research, Donanemab, Clinical pharmacology review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_66_1","volume-title":"Center for Drug Evaluation and Research, Dostarlimab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.798"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13363"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.982"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696385"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1698"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae068"},{"key":"e_1_2_9_74_1","volume-title":"Center for Drug Evaluation and Research, Emapalumab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-650226"},{"key":"e_1_2_9_76_1","volume-title":"Center for Drug Evaluation and Research, Epcoritamab, Multi\u2010discipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_77_1","volume-title":"Center for Drug Evaluation and Research, Eptinezumab, Clinical pharmacology review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_78_1","volume-title":"Center for Drug Evaluation and Research, Erenumab, Clinical pharmacology review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.10.013"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13767"},{"key":"e_1_2_9_81_1","volume-title":"Center for Drug Evaluation and Research, Evolocumab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_82_1","volume-title":"Center for Drug Evaluation and Research, Faricimab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418771376"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.3999\/jscpt.48.131"},{"key":"e_1_2_9_85_1","volume-title":"Center for Drug Evaluation and Research, Garadacimab, Integrated review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_86_1","volume-title":"Center for Drug Evaluation and Research, Glofitamab, Multi\u2010discipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009355162"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16236"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2110-5"},{"key":"e_1_2_9_90_1","volume-title":"Center for Drug Evaluation and Research, Ibalizumab, Clinical review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12029"},{"key":"e_1_2_9_92_1","volume-title":"Center for Drug Evaluation and Research, Idarucizumab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02635-9"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517740641"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2015.1022297"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-009-0158-0"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0243-5"},{"key":"e_1_2_9_98_1","first-page":"7","article-title":"Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma","volume":"13","author":"Weber J","year":"2013","journal-title":"Cancer Immun"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14657"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0198-4"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15034"},{"key":"e_1_2_9_102_1","unstructured":"ClinicalTrials.gov NCT03401671.Study of lanadelumab in healthy Japanese and matched Caucasian adult subjects.https:\/\/clinicaltrials.gov\/study\/NCT03401671"},{"key":"e_1_2_9_103_1","volume-title":"Center for Drug Evaluation and Research, Lebrikizumab, Multi\u2010discipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12862"},{"key":"e_1_2_9_105_1","volume-title":"Center for Drug Evaluation and Research, Lecanemab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_106_1","volume-title":"Center for Drug Evaluation and Research, Linvoseltamab, Multi\u2010discipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_107_1","volume-title":"Center for Drug Evaluation and Research, Margetuximab, Multi\u2010discipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_108_1","volume-title":"Center for Drug Evaluation and Research, Marstacimab, Integrated review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.205"},{"key":"e_1_2_9_110_1","volume-title":"Center for Drug Evaluation and Research, Mirikizumab, Multi\u2010discipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1564"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad082"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13825"},{"key":"e_1_2_9_114_1","volume-title":"Center for Drug Evaluation and Research, Narsoplimab, Integrated review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_115_1","article-title":"Comparison of nadir serum concentrations in the extended dosing therapy of natalizumab between American and Japanese multiple sclerosis patients","volume":"2","author":"Tanaka M","year":"2016","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3154-z"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2425"},{"key":"e_1_2_9_118_1","volume-title":"Center for Drug Evaluation and Research, Nemolizumab, Integrated review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_119_1","volume-title":"Center for Drug Evaluation and Research, Nipocalimab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_120_1","volume-title":"Center for Drug Evaluation and Research, Nirsevimab, Integrated review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12143"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0669-y"},{"key":"e_1_2_9_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12040"},{"key":"e_1_2_9_124_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211055934"},{"key":"e_1_2_9_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12444"},{"key":"e_1_2_9_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2389-9"},{"key":"e_1_2_9_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2015.12.003"},{"issue":"2","key":"e_1_2_9_128_1","first-page":"216","article-title":"Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high\u2010risk infants","volume":"14","author":"Lanari M","year":"2013","journal-title":"Curr Drug Metab"},{"key":"e_1_2_9_129_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009344989"},{"key":"e_1_2_9_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0347-6"},{"key":"e_1_2_9_131_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607"},{"key":"e_1_2_9_132_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyp006"},{"key":"e_1_2_9_133_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.184"},{"key":"e_1_2_9_134_1","volume-title":"Center for Drug Evaluation and Research, Pozelimab, Multidiscipline review","author":"US Food and Drug Administration"},{"issue":"7","key":"e_1_2_9_135_1","first-page":"4003","article-title":"Safety and Pharmacokinetics of Second\u2010line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma","volume":"35","author":"Yoshino T","year":"2015","journal-title":"Anticancer Res"},{"key":"e_1_2_9_136_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv144"},{"key":"e_1_2_9_137_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2009.01843.x"},{"key":"e_1_2_9_138_1","volume-title":"Center for Drug Evaluation and Research, Ranibizumab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_139_1","volume-title":"Center for Drug Evaluation and Research, Raxibacumab, Clinical pharmacology review"},{"key":"e_1_2_9_140_1","volume-title":"Center for Drug Evaluation and Research, Relatlimab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_141_1","volume-title":"Center for Drug Evaluation and Research, Reslizumab, Clinical pharmacology review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_142_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6980"},{"key":"e_1_2_9_143_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1473"},{"key":"e_1_2_9_144_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_9_145_1","volume-title":"Center for Drug Evaluation and Research, Romosozumab, Multi\u2010discipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_146_1","volume-title":"Center for Drug Evaluation and Research, Rozanolixizumab, Integrated review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_147_1","volume-title":"Center for Drug Evaluation and Research, Sarilumab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_148_1","volume-title":"Center for Drug Evaluation and Research, Secukinumab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_149_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1316"},{"key":"e_1_2_9_150_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1743-y"},{"key":"e_1_2_9_151_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3349"},{"key":"e_1_2_9_152_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01176-5"},{"key":"e_1_2_9_153_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.122.001511"},{"key":"e_1_2_9_154_1","volume-title":"Center for Drug Evaluation and Research, Sutimlimab, Clinical pharmacology and biopharmaceutics review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_155_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70306"},{"key":"e_1_2_9_156_1","volume-title":"Center for Drug Evaluation and Research, Talquetamab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_157_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03884-z"},{"key":"e_1_2_9_158_1","volume-title":"Center for Drug Evaluation and Research, Teplizumab, Clinical pharmacology review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_159_1","volume-title":"Center for Drug Evaluation and Research, Teprotumumab, Clinical pharmacology review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_160_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.775"},{"key":"e_1_2_9_161_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1401"},{"key":"e_1_2_9_162_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202176"},{"key":"e_1_2_9_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.07.014"},{"key":"e_1_2_9_164_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.11.33"},{"key":"e_1_2_9_165_1","volume-title":"Center for Drug Evaluation and Research, Toripalimab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2017.12.001"},{"key":"e_1_2_9_167_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0153-2"},{"key":"e_1_2_9_168_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12464"},{"key":"e_1_2_9_169_1","volume-title":"Center for Drug Evaluation and Research, Tremelimumab, Clinical pharmacology review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_170_1","volume-title":"Center for Drug Evaluation and Research, Ublituximab, Clinical pharmacology review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_171_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2215426"},{"key":"e_1_2_9_172_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1307"},{"key":"e_1_2_9_173_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21896"},{"key":"e_1_2_9_174_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13243"},{"key":"e_1_2_9_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.643"},{"key":"e_1_2_9_176_1","volume-title":"Center for Drug Evaluation and Research, Zenocutuzumab, Multidiscipline review","author":"US Food and Drug Administration"},{"key":"e_1_2_9_177_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e16078"},{"key":"e_1_2_9_178_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011"},{"key":"e_1_2_9_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.11.002"},{"key":"e_1_2_9_180_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"e_1_2_9_181_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000996"},{"key":"e_1_2_9_182_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03771-z"},{"key":"e_1_2_9_183_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982806"},{"key":"e_1_2_9_184_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"e_1_2_9_185_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612"},{"key":"e_1_2_9_186_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1927"},{"key":"e_1_2_9_187_1","doi-asserted-by":"publisher","DOI":"10.2165\/11584340-000000000-00000"},{"key":"e_1_2_9_188_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.4921.4921"},{"key":"e_1_2_9_189_1","doi-asserted-by":"publisher","DOI":"10.2165\/11535960-000000000-00000"},{"key":"e_1_2_9_190_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0181-6"},{"key":"e_1_2_9_191_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.11.013"},{"key":"e_1_2_9_192_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-30023-3_6"},{"key":"e_1_2_9_193_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_2_9_194_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1041917"},{"key":"e_1_2_9_195_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-0031-y"},{"key":"e_1_2_9_196_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155"},{"key":"e_1_2_9_197_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2762"},{"key":"e_1_2_9_198_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2005.02158.x"},{"key":"e_1_2_9_199_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-10-RG-067"},{"key":"e_1_2_9_200_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70080"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70245","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:33:20Z","timestamp":1787661200000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":199,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/jcph.70245"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70245","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"2026-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70245"}}